Pharming Group N.V. (AMS: PHARM)
Netherlands
· Delayed Price · Currency is EUR
0.691
-0.011 (-1.57%)
Nov 21, 2024, 1:05 PM CET
Pharming Group Revenue
Pharming Group had revenue of $74.85M USD in the quarter ending September 30, 2024, with 12.22% growth. This brings the company's revenue in the last twelve months to $285.75M, up 30.64% year-over-year. In the year 2023, Pharming Group had annual revenue of $245.32M with 19.30% growth.
Revenue (ttm)
$285.75M
Revenue Growth
+30.64%
P/S Ratio
1.77
Revenue / Employee
$748.02K
Employees
382
Market Cap
471.46M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 245.32M | 39.69M | 19.30% |
Dec 31, 2022 | 205.62M | 6.75M | 3.39% |
Dec 31, 2021 | 198.87M | -13.30M | -6.27% |
Dec 31, 2020 | 212.17M | 22.79M | 12.03% |
Jan 1, 2020 | 189.39M | 54.26M | 40.15% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Galapagos NV | 260.09M |
ASML Holding N.V. | 26.24B |
Unilever PLC | 60.29B |
Prosus N.V. | 5.07B |
RELX PLC | 10.97B |
ING Groep N.V. | 17.21B |
Pharming Group News
- 12 days ago - Morgan Stanley's Strategic Acquisition of Pharming Group Shares - GuruFocus
- 16 days ago - Pharming Group to participate in November investor conference - GlobeNewsWire
- 4 weeks ago - Pharming Group N.V. (PHAR) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Pharming Group N.V. 2024 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 4 weeks ago - Pharming reports Q3 results - Seeking Alpha
- 6 weeks ago - Pharming Group to report third quarter 2024 financial results on October 24 - GlobeNewsWire
- 6 weeks ago - Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation - GlobeNewsWire
- 2 months ago - Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib) - GlobeNewsWire